TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Non-Small Cell Lung Cancer (NSq-NSCLC) (TRAIL, an Interim Analysis)
분야
의약학 > 내과학
저자
김영철 , 김규식 , 김윤섭 , 김철현 , 양세훈 , 유정선 , 윤성호 , 이관호 , 이정은 , 이민기 , 오인재 , 용석중 , 이계영 , 인광호 , 장승훈 , 장중현 , 장태원 , 정치영
발행기관
대한결핵 및 호흡기학회
간행물정보
대한결핵및호흡기학회 추계학술발표초록집 2012년, 제114권 144(총1페이지)
파일형식
0y909796.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    1,000원
    적립금
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    영문초록
    Platinum (P) doublet with either Pemetrexed (Alimta, A) or Docetaxel (D) is considered as a standard first line regimen for NSq-NSCLC. D is being used in 60 mg/m2 3 weekly dosage in Japan and several east Asian countries instead of 75 mg/m2 3 weekly dose of western countries. In this prospective randomized trial, we are recruiting patients with chemo naïve stage IV NSq-NSCLC to compare DP 60 and 70 mg/m3 3 weekly regimen and AP 500 and 70 mg/m2 3 weekly regimen. To prove non-inferiority of progression free survival of DP compared to AP, 276 patients will be enrolled to this trial. Since August 2011, 72 patients (48 male, 24 female, mean age 62.6 years) were enrolled to this trial. Patients were randomized into AP group (n=37) or DP group (n=35). Number of cycles and dose reduction rate are not different in both groups, respectively (AP: 2.7 cycles, 18.2% vs. DP: 2.4 cycles, 22.6%, p>0.05). Similar response rate are being observed in both groups (AP: 7/37 (18.9%) vs. DP: 7/35 (20.0%)). In this interim analysis both AP and DP regimens are well tolerated, and show similar efficacy. Active recruitment should be followed to prove significant clinical evidence (ClinicalTrials.gov Identifier: NCT01282151).
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일 help@reportshop.co.kr
    copyright (c) 2009 happynlife. steel All reserved.